VKTXViking Therapeutics, Inc.

Nasdaq vikingtherapeutics.com


$ 63.25 $ 0.82 (1.31 %)    

Thursday, 12-Sep-2024 11:52:35 EDT
QQQ $ 468.73 $ 0.10 (0.02 %)
DIA $ 409.12 $ -0.34 (-0.08 %)
SPY $ 554.52 $ -0.47 (-0.08 %)
TLT $ 100.09 $ -0.28 (-0.28 %)
GLD $ 235.99 $ 1.35 (0.58 %)
$ 60.83
$ 62.43
$ 50.00 x 100
$ 63.55 x 112
$ 62.61 - $ 64.62
$ 8.28 - $ 99.41
5,558,538
na
6.74B
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-24-2024 06-30-2024 10-Q
2 04-25-2024 03-31-2024 10-Q
3 02-07-2024 12-31-2023 10-K
4 10-25-2023 09-30-2023 10-Q
5 07-26-2023 06-30-2023 10-Q
6 04-26-2023 03-31-2023 10-Q
7 02-10-2023 12-31-2022 10-K
8 10-26-2022 09-30-2022 10-Q
9 07-27-2022 06-30-2022 10-Q
10 04-27-2022 03-31-2022 10-Q
11 02-09-2022 12-31-2021 10-K
12 11-03-2021 09-30-2021 10-Q
13 07-28-2021 06-30-2021 10-Q
14 04-28-2021 03-31-2021 10-Q
15 02-17-2021 12-31-2020 10-K
16 10-28-2020 09-30-2020 10-Q
17 07-29-2020 06-30-2020 10-Q
18 04-30-2020 03-31-2020 10-Q
19 02-26-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 03-13-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 03-07-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 03-21-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-08-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 08-14-2015 06-30-2015 10-Q
38 06-12-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 morgan-stanley-reiterates-overweight-on-viking-therapeutics-maintains-105-price-target

Morgan Stanley analyst Michael Ulz reiterates Viking Therapeutics (NASDAQ:VKTX) with a Overweight and maintains $105 price t...

 viking-therapeutics-stock-could-soar-45-ahead-of-key-weight-loss-drug-readout-jpmorgan

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price ta...

 jp-morgan-initiates-coverage-on-viking-therapeutics-with-overweight-rating-announces-price-target-of-80

JP Morgan analyst Hardik Parikh initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Overweight rating and announc...

 fake-ozempic-targets-weight-loss-market-forged-batches-an-international-concern

Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation...

Core News & Articles

- Reuters 

 jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics

Jim Cramer discusses Serve Robotics, Builders FirstSource, Vertex Pharmaceuticals and Viking Therapeutics on CNBC.

 viasat--ast-spacemobile-are-among-top-6-mid-cap-stocks-that-shined-the-brightest-last-week-july-21-july-27-are-the-others-in-your-portfolio

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

 novo-nordisk-shares-decline-amid-competitive-pressure

Novo Nordisk A/S Common Stock (NYSE: NVO) experienced a notable decline on Thursday. This movement follows a significant announ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION